AffiliationUniv Arizona, Dept Basic Med Sci, Coll Med Phoenix
MetadataShow full item record
CitationAlQudah, M., Hale, T. M., & Czubryt, M. P. (2020). Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biology, 91, 92-108.
RightsCopyright © 2020 Elsevier B.V. All rights reserved.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractFibrosis is characterized by excessive deposition of extracellular matrix components such as collagen in tis-sues or organs. Fibrosis can develop in the heart, kidneys, liver, skin or any other body organ in response to injury or maladaptive reparative processes, reducing overall function and leading eventually to organ failure. A variety of cellular and molecular signaling mechanisms are involved in the pathogenesis of fibrosis. The renin-angiotensin-aldosterone system (RAAS) interacts with the potent Transforming Growth Factor beta (TGF beta) pro-fibrotic pathway to mediate fibrosis in many cell and tissue types. RAAS consists of both classical and alternative pathways, which act to potentiate or antagonize fibrotic signaling mechanisms, respectively. This review provides an overview of recent literature describing the roles of RAAS in the pathogenesis of fibrosis, particularly in the liver, heart, kidney and skin, and with a focus on RAAS interactions with TGF beta sig-naling. Targeting RAAS to combat fibrosis represents a promising therapeutic approach, particularly given the lack of strategies for treating fibrosis as its own entity, thus animal and clinical studies to examine the impact of natural and synthetic substances to alter RAAS signaling as a means to treat fibrosis are reviewed as well. (c) 2020 Elsevier B.V. All rights reserved.
Note12 month embargo; published online 16 May 2020
VersionFinal accepted manuscript
- Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?
- Authors: Emdin M, Fatini C, Mirizzi G, Poletti R, Borrelli C, Prontera C, Latini R, Passino C, Clerico A, Vergaro G
- Issue date: 2015 Mar 30
- Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts.
- Authors: Leifheit-Nestler M, Kirchhoff F, Nespor J, Richter B, Soetje B, Klintschar M, Heineke J, Haffner D
- Issue date: 2018 Oct 1
- Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis.
- Authors: de Jong MA, Mirkovic K, Mencke R, Hoenderop JG, Bindels RJ, Vervloet MG, Hillebrands JL, van den Born J, Navis G, de Borst MH, NIGRAM consortium.
- Issue date: 2017 Jan 1
- Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension.
- Authors: Muñoz-Durango N, Fuentes CA, Castillo AE, González-Gómez LM, Vecchiola A, Fardella CE, Kalergis AM
- Issue date: 2016 Jun 23
- RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
- Authors: Koszegi S, Molnar A, Lenart L, Hodrea J, Balogh DB, Lakat T, Szkibinszkij E, Hosszu A, Sparding N, Genovese F, Wagner L, Vannay A, Szabo AJ, Fekete A
- Issue date: 2019 Jan